CGRP antibodies work equally well for medication overuse headache without needing analgesic detoxification | Research

The takeaway

In 200 patients with chronic migraine and medication overuse headache, CGRP monoclonal antibodies were equally effective whether or not patients underwent analgesic detoxification, for both simple and complex MOH phenotypes.

No detox needed
CGRP antibodies eliminated the need for painful analgesic withdrawal in medication overuse headache—a paradigm shift for 200 patients with both simple and complex MOH

What the researchers found

Both simple and complex MOH patients improved significantly on CGRP-mAbs at months 1, 3, and 6. Adding detoxification provided no additional benefit (p>0.05 for all comparisons). Reduced: headache frequency, intensity, duration, acute medication days. 200 patients total.

Why it matters

Analgesic detoxification is unpleasant and a barrier to MOH treatment. Showing that CGRP-mAbs work without it could encourage more patients to seek treatment and simplify clinical management of this common and disabling condition.

How the study worked

Six-month observational study of 200 chronic migraine/MOH patients on subcutaneous CGRP-mAbs. Stratified by MOH complexity and detoxification strategy. Outcomes at 1, 3, and 6 months.

What this study cannot tell us

Observational, non-randomized. Selection bias possible. Single center. Six-month follow-up may not capture all relapse patterns. CGRP-mAb type not specified.

How to read the evidence

Large observational study (200 patients). Good real-world evidence but needs randomized confirmation.

When this study was published

Published in 2025.

The bigger picture

This study supports a paradigm shift in MOH management: from mandatory analgesic withdrawal to CGRP-mAb-first approach. The natural reduction in analgesic use following CGRP-mAb treatment suggests the headache—not the medication—is the primary driver of overuse.

Questions still open

Will randomized trials confirm that detoxification is unnecessary with CGRP-mAbs?
Does early CGRP-mAb initiation without detox improve long-term MOH outcomes?
Could this approach be extended to other preventive migraine treatments?

Common questions

Do I need to stop painkillers before starting CGRP treatment for chronic migraine?

This study of 200 patients found that CGRP antibody injections worked equally well whether or not patients stopped their pain medications first. Analgesic use naturally decreased as the CGRP treatment reduced headache frequency. This challenges the traditional requirement for painful medication withdrawal.

What is medication overuse headache?

MOH occurs when taking pain medications too frequently (typically >10-15 days/month) paradoxically worsens and perpetuates headaches. Traditionally, treatment required stopping all pain medications (detoxification)—an unpleasant process. This study shows CGRP antibodies can break the cycle without requiring that difficult step.

Read the original research

No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies.

Cephalalgia : an international journal of headache, 45(6), 3331024251329808

View on PubMed ↗Publisher’s paper ↗

Citation

Silvestro, Marcello; Orologio, Ilaria; Sozio, Pasquale; Dortucci, Valentina; Trojsi, Francesca; Siciliano, Mattia; Tedeschi, Gioacchino; Tessitore, Alessandro; Russo, Antonio. (2025). No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies.. Cephalalgia : an international journal of headache, 45(6), 3331024251329808. https://doi.org/10.1177/03331024251329808